 |
IDEA Collider: Innovation & Asymmetric Learning in PharmaAuthor: IDEA Pharma, SAI MedPartners
IDEA Collider explores how asymmetric learning drives bold innovation in the pharmaceutical and life sciences industries. The podcast features conversations with top thinkers, scientists, and strategists who challenge the status quo to spark real progress in drug development, biotech, and healthcare. Each episode dives into how organizations can make smarter decisions earlier, reimagine R&D, and unlock competitive advantage through differentiated thinking. Questions We Explore * What is asymmetric learning, and how does it fuel pharma innovation? * Why do some organizations outpace othersand what can we learn from them? * How can we overcome barriers to meaningful progress in healthcare? * Whats broken in traditional innovation modelsand how do we fix it? Listen and subscribe on all major platforms. Language: en Genres: Business, Life Sciences, Marketing, Science Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
ESMO 2026 Preview: Key studies that could fundamentally change the oncology landscape.
Episode 21
Thursday, 22 October, 2026
In this episode of the IDEA Collider podcast, Alex Gray, Chief Medical Officer at SAI & IDEA Pharma, John Barry, Executive Vice President at SAI, and Tom Brockbank, Senior Consultant at IDEA Pharma, look ahead to ESMO 2026 and some of the key clinical datasets that could shape the next phase of oncology innovation.Together, they discuss whether T-cell engagers can deliver transformative survival benefits in earlier lines of solid tumours with tarlatamab in DeLLphi-305; the promising science behind PD-1×VEGF combinations with Ivonescimab in HARMONi-GI1 and how we believe Merck & Co., Inc. are perceiving them; and Krascendo 1, a true head-to-head study that could help define a best-in-class KRAS G12C therapy and shape the future of the treatment landscape.Listen now to hear which studies the team are most excited about - and share the ESMO data you will be watching most closely. The IDEA and SAI teams will be in Madrid and look forward to connecting with colleagues to discuss the implications further.www.ideapharma.comwww.sai-med.com
